Sequential chemotherapy of advanced colorectal cancer with standard or high-dose methotrexate followed by 5-fluorouracil
β Scribed by Solan, Andrew ;Vogl, Steven E. ;Kaplan, Barry H. ;Berenzweig, Marc ;Richard, Joseph ;Lanham, Richard
- Publisher
- John Wiley and Sons
- Year
- 1982
- Tongue
- English
- Weight
- 313 KB
- Volume
- 10
- Category
- Article
- ISSN
- 0098-1532
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
Thirty patients with advanced measurable colorectal cancer were randomized to receive either methotrexate (MTX) 200 mg/m^2^ or 40 mg/m^2^, followed in four hours by 5βfluorouracil (5βFU) 600 mg/m^2^. Patients receiving the higher dose MTX were given leucovorin rescue 24 hours later. Eight of 13 patients treated with 200 mg/m^2^ MTX + 5βFU developed severe hematologic toxicity, leading to two toxic deaths. In addition, 9/13 developed mild azotemia, and three patients had severe gastrointestinal toxicity. No patients with prior chemotherapy responded to either regimen. Among those without prior chemotherapy, there were two of six and three of eight partial responses, respectively, in the 200 mg/m^2^ and 40 mg/m^2^ MTX regimens. Sequential 200 mg/m^2^ MTX followed by 5βFU after four hours has unacceptable toxicity. Sequential treatment with standard dose MTX + 5βFU is tolerable and merits further study.
π SIMILAR VOLUMES
Background. In a previous Phase I1 trial, the authors showed that a weekly continuous infusion of 5-fluorouracil (5-FU) at a dose of 3.5 g/mz for 48 hours is an active treatment for advanced colorectal cancer. The overall response rate was 38.5%, and the median survival was 12 months. These data wer
Background. Metastatic colorectal cancer is generally incurable. The most active regimen available, 5-fluorouracil(5-FU) and folinic acid (Leucovorin), produces response rates of approximately 25% to 30%. Methyl-lomustine is a nitrosourea with modest activity against colorectal cancer. A randomized